Free Newsletter
Insurers still pressing Lilly on Zyprexa
Free newsletter via e-mail
Tools
Eli Lilly still faces legal action on its Zyprexa mismarketing, despite having paid a $1.4 billion settlement recently to state prosecutors and a separate $1.2 billion to settle with individual patient plaintiffs. What's left? Insurers. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: